Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Specific immunotherapy of birch pollen-related food (apple) allergy
2011-001221-24Phase 2Completed
- Sponsor
- Medical University of Vienna
- Start
- Dec 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, single-arm trial of rMal d 1 and recombinant Bet v 1 in food allergy and birch pollen allergy, sponsored by Medical University of Vienna. Primary endpoint: Reactivity in skin prick tests, intradermal tests and oral provocation tests. Started Dec 2011; status: completed.
02
Drugs
rMal d 1recombinant Bet v 1
03
Conditions
food allergybirch pollen allergy
Beyond the preview
Go deeper on 2011-001221-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001221-24.